An insightful piece in IAM from Gareth Jones of BenevolentAI. Gareth talks about how new uses of data in the pharma and life science sectors, coupled with the management of data sources in complex data licensing landscapes, brings real challenges and demands a multitude of different skills.
The piece contains an interesting glimpse into some of the IP-commercial and legal hurdles being grappled with by leading data businesses.
We continue to be fascinated by the way that evolving technologies test our IP systems and licensing models, and it is for the IP community to drive pragmatic and efficient ways to unlock the commercial potential for the businesses we work in.
From diagnosis support to biological engineering, AI has the potential to reshape the entire pharmaceutical industry. Gareth Jones at BenevolentAI provides a number of tips on how IP professionals can adapt their strategies as data becomes key to revenue